NasdaqCM:PLSEMedical Equipment
What Pulse Biosciences (PLSE)'s Mixed Q1 Results and nPulse AF Data Reveal for Shareholders
Pulse Biosciences recently reported first-quarter 2026 results showing a wider net loss of US$18.58 million and basic loss per share of US$0.27, while also missing consensus revenue expectations with about US$0.4 million in sales.
At the same time, the company released late-breaking, positive first-in-human data for its nPulse Cardiac Catheter System in atrial fibrillation, reinforcing confidence in its non-thermal nsPFA platform with high procedural success, durable rhythm control and a low...